Clinical Trial Update: Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC Refractory to 1st-line Oxaliplatin Base Therapy [Phase 1]

View source ↗

Summary

A completed Phase I pharmacokinetic study evaluating biweekly PEP02 in metastatic colorectal cancer refractory to first-line oxaliplatin-based therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• PEP02

Snippet

Sponsor: PharmaEngine | Conditions: Metastatic Colorectal Cancer | Phase 1 | Status: COMPLETED